Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-30

Clinical Trial Update: AAVCAGsCD59 for the Treatment of Wet AMD [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating AAVCAGsCD59 for wet age-related macular degeneration has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AAVCAGsCD59

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Wet Age-related Macular Degeneration | Phase 1 | Status: COMPLETED